 |
Mesoblast Limited Company Summary |
 Mesoblast Limited (ASX:MSB)(USOTC:MBLTY) is an Australian biotechnology company committed to the development of novel treatments for orthopaedic conditions, including the rapid commercialisation of a unique adult stem cell technology aimed at the regeneration and repair of bone and cartilage. Our focus is to progress through clinical trials and international regulatory processes necessary to commercialise the technology in as short a timeframe as possible.
Mesoblast has the worldwide exclusive rights for a series of patents and technologies that have been developed over more than 10 years and which relate to the identification, extraction and culture of adult Mesenchymal Precursor Cells (MPCs). The Company has also acquired a substantial interest in Angioblast Systems Inc, an American company developing the platform MPC technology for the treatment of cardiovascular diseases, including repair and regeneration of blood vessels and heart muscle. Mesoblast and Angioblast are jointly funding and progressing the core technology. Mesoblast's strategy is to maximise shareholder value through both corporate partnerships and the rapid and successful completion of clinical milestones.
|
|
 |
DIRECTORS / OFFICERS |
 Professor Silviu Itescu, MBBS (Hons), FRACP, FACP, FACR
Director and Chief Scientific Adviser
Professor Itescu is the Founder of Mesoblast Limited and Angioblast Systems, Inc. Most recently Director of Transplantation Immunology at New York's Columbia University Medical Center, Professor Itescu has established an outstanding international reputation in the fields of stem cell biology, autoimmune diseases, organ transplantation and heart failure. His experiences range from laboratory research to new drug development and clinical evaluation. Professor Itescu pioneered novel approaches to the use of adult stem cells for the treatment of heart disease and is leading international collaborative trials in this area.
|
|
|
|
|
COMPANY DATA |
 |
Fax |
(03) 9639 6030 |
 |
|
Principal Sector |
Health & Pharm |
|
|
Principal Industry |
Biotechnology |
|
|
Listed |
2004/12/16 |
|
|
Homepage |
www.mesoblast.com |
|
| |
|
|
MARKETS |
|
|
|
OTHER LANGUAGES |
|
|
|
|
|
NEWS |
 |
| |  Australian Market Report of June 24: Higher Commodities Not Enough to Placate Investors (JUNE 24, 2009) | | Mesoblast Limited's (ASX:MSB) First Patients In Bone Marrow Transplant Trial Show Earlier Engraftment (JUNE 24, 2009) | | Australian Market Report of May 14: Disappointment Over US Retail Sales (MAY 14, 2009) | | Mesoblast Limited (ASX:MSB) Announce Heart Muscle Function Improved Significantly After Single, Lowest-Dose Injection Of "Off-The-Shelf" Stem Cells In Patients With Heart Failure (MAY 14, 2009) | | Mesoblast Limited (ASX:MSB) Chairman's Letter to Shareholders (MAY 5, 2009) | | Mesoblast Limited (ASX:MSB) Commences Clinical Program For Fusion Of Cervical Spine (APR 28, 2009) | | Mesoblast Limited (ASX:MSB) Completes Equity Raising For Clinical Programs (APR 1, 2009) | | Mesoblast Limited (ASX:MSB) Raises Capital Of A$10.81 Million For New Clinical Programs (MAR 30, 2009) | | Mesoblast Limited (ASX:MSB) Presents Positive Adult Stem Cell Results To American Academy of Orthopedic Surgeons (AAOS) (FEB 27, 2009) | | Mesoblast Limited (ASX:MSB) Emerging Portfolio of Clinical Products Underpin Commercial Strategic Objectives (FEB 26, 2009) | | Mesoblast Limited (ASX:MSB) First Group Of Heart Failure Patients Treated With "Off-The-Shelf" Adult Stem Cells Successfully Pass Key Safety Milestone (FEB 25, 2009) | | Mesoblast Limited (ASX:MSB) To Provide Cutting Edge Treatment Using Proprietary Adult Stem Cell Products (FEB 16, 2009) | | Australian Market Report of January 20: Bad News from UK (JAN 20, 2009) | | Mesoblast Limited (ASX:MSB) Stem Cells Approved For World First Osteoathritis Clinical Trial (JAN 20, 2009) | | Mesoblast Limited (ASX:MSB) Named 2009 North American Emerging Company By Frost & Sullivan (JAN 6, 2009) | | Mesoblast Limited (ASX:MSB) "The Year in Review" Address By Chairman Brian Jamieson (NOV 28, 2008) | | Mesoblast Limited (ASX:MSB) Selected As US Stem Cell Market Innovation of the Year by Frost and Sullivan (NOV 14, 2008) | | Mesoblast Limited (ASX:MSB) Proprietary Stem Cells For Heart Failure Highlighted At Major Cardiology Conference (NOV 11, 2008) | | Mesoblast Limited (ASX:MSB) Featured At UBS Healthcare Investor Conference (NOV 7, 2008) | | Mesoblast Limited (ASX:MSB) Bone Marrow Transplant Trial Receives US FDA Clearance (NOV 5, 2008) |
|
|
